NCT03600376View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 19, 2018

Primary Completion Date

August 14, 2019

Study Completion Date

August 14, 2019

Conditions
Exertional Heat Stroke
Interventions
DRUG

Ryanodex and Standard of Care

Ryanodex to be administered as a rapid IV push

OTHER

Standard of Care

Body cooling measures and supportive measures

Trial Locations (4)

Unknown

King Faisal Hospital, Mecca

Mina al Jisr Hospital, Miná

Mina Al-Shari Al-Jadeed Hospital, Miná

Mina Al-Wadi Hospital, Miná

Sponsors
All Listed Sponsors
lead

Eagle Pharmaceuticals, Inc.

INDUSTRY

NCT03600376 - Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS | Biotech Hunter | Biotech Hunter